Trial reportBritish journal of haematology2020
Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide.
Trial report in British journal of haematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Functional ovarian reserve in women with Sickle Cell disease: A systematic review.JBRA assisted reproduction · 2024Pooled it
- Effects of hydroxyurea on fertility in male and female sickle cell disease patients. A systemic review and meta-analysis.PloS one · 2024Pooled it
- Hydroxyurea (hydroxycarbamide) for sickle cell disease.The Cochrane database of systematic reviews · 2022Pooled it
- Growth and puberty in African children with sickle cell anemia treated with hydroxyurea.Blood advances · 2026Trial
- Gynecologic and Reproductive Health in Patients with Sickle Cell Disease: Underrecognized Challenges and Care Management Opportunities.Journal of clinical medicine · 2026Review
- Therapeutic mechanisms of Zi Chong granules against hydroxyurea-induced diminished ovarian reserve based on integrated multi-omics analyses.Journal of ovarian research · 2025Article
- Follicular Fluid Metabolomics: Tool for Predicting IVF Outcomes of Different Infertility Causes.Reproductive sciences (Thousand Oaks, Calif.) · 2025Review
- Article
- Pregnancy: MPN management before, during, and after pregnancy.Hematology. American Society of Hematology. Education Program · 2024Review
- Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management.Expert review of hematology · 2024Review
- Impact of hydroxyurea on follicle density in patients with sickle cell disease.Blood advances · 2024Article
- Hydroxyurea and follicle density in sickle cell.Blood advances · 2024Article
- The impact of sickle cell disease and its treatment on ovarian reserve in reproductive-aged Black women.British journal of haematology · 2024Article
- Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women.Expert review of hematology · 2024Review
- Detrimental effects of sickle cell disease and hydroxycarbamide on ovarian reserve but uncertain impact on fertility.Blood advances · 2023Article
- Impact of vitamin B12 on the reproductive health of women with sickle cell disease: a narrative review.Reproduction & fertility · 2023Article
- Infertility and treatment-seeking practices among females and males with sickle cell disease in the Sickle Cell Disease Implementation Consortium registry.Pediatric blood & cancer · 2023Article
- Expecting more: the case for incorporating fertility services into comprehensive sickle cell disease care.The Lancet. Haematology · 2023Review
- Knowledge of fertility and perception of fertility treatment among adults with sickle cell disease (KNOW FERTILITY).Frontiers in global women's health · 2023Article
- Incorporating gonadal health counseling into pediatric care of sickle cell patients.Hematology. American Society of Hematology. Education Program · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The application of modern ovarian reserve measures to women with sickle cell disease (SCD) may help answer longstanding questions about whether SCD or hydroxycarbamide (HC; also known as hydroxyurea) affect women's reproductive lifespan. Anti-Müllerian hormone (AMH), an established marker of ovarian reserve, is used to assess the ovarian follicle pool. We used a standard clinical assay to measure AMH in 285 banked samples from 93 female subjects with haemoglobin SS from the historic Multicenter Study of Hydroxyurea (MSH), which led to the United States Food and Drug Administration approval of HC for adults with SCD. No samples from the randomised portion of the MSH remain, so samples from the decade-long MSH follow-up studies were analysed. Most subjects were exposed to HC (86/93). The median AMH levels were lower in study subjects than in age- and sex-matched reference values. The median AMH levels consistent with diminished ovarian reserve, a risk factor for infertility, occurred in subjects starting at the age of 25-30 years; in healthy women, this occurs after the age of 40 years. In multivariate analysis, taking HC was independently associated with a low AMH (β = 0·001, 95% confidence interval -0·002 to 0·000; P = 0·006). These results suggest that ovarian reserve is prematurely reduced in women with haemoglobin SS and raise the possibility that HC contributes to this finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.